Hua Medicine
PublicHua Medicine is now publicly traded
The data on this page reflects Hua Medicine's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 14, 2018
Last Round
Series D
Mar 27, 2018
Total Funding Raised
$374.74M
Company Overview
Hua Medicine (HKG: 02552) is a biopharmaceutical company focused on the development and commercialization of Dorzagliatin (HMS5552), a first-in-class oral medication for the treatment of Type 2 diabetes, primarily operating in the PRC.
Sector
Biotech
AI Layer
Non-AI
Keywords
Hua Medicine Comparables
Compare Hua Medicine with similar companies based on industry and business-model similarity.
No public comparables are available for Hua Medicine. Request access to learn about comparables coverage.
Request accessHua Medicine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Sep 14, 2018 | ||||
| Series D | Mar 27, 2018 | ||||
| Series C | Apr 22, 2016 | ||||
| Series B | Jan 8, 2015 | ||||
| Series A | May 16, 2014 | ||||
Series A | Sep 20, 2011 |
Hua Medicine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Guotai Junan Securities (Hong Kong) Limited | IPO |
| Harvest Global Investments | Series C |
| Frontline BioVentures | Series C, Series B |
| Harvest Global Investments | Series C, Series D |
| Blue Pool Capital | Series D |
| Ally Bridge Group | Series D, Series C, Series B |
| TF Capital | Series C, Series B |
Hua Medicine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access